Skip to main content
Careers
Contact us
Company
About Us
Management
Board of Directors
Advisory Board
Scientific Team
Therapeutic Focus
Genetic Disorders
Oncology
Science and Technology
SNA Platform
References and Papers
Pipeline
Pipeline
Cavrotolimod (AST-008)
XCUR-FXN
Collaboration Programs
Compassionate Use Policy
Partnering and Licensing
Investors
Investors
News
Events & Presentations
Stock Info
Stock Quote & Chart
Analyst Coverage
Financials
Interactive Financials
Financial Summary
SEC Filings
Annual Reports
Governance
Executive Management
Board of Directors
Governance Documents
Committee Composition
Resources
Contact IR
FAQs
Email Alerts
News
Company
About Us
Management
Board of Directors
Advisory Board
Scientific Team
Therapeutic Focus
Genetic Disorders
Oncology
Science and Technology
Pipeline
Pipeline
AST-008
XCUR-FXN
Collaboration Programs
Compassionate Use Policy
Partnering and Licensing
Investors
Investors
News
Events & Presentations
Stock Info
Stock Quote & Chart
Analyst Coverage
Financials
Interactive Financials
Financial Summary
SEC Filings
Annual Reports
Governance
Executive Management
Board of Directors
Governance Documents
Committee Composition
Resources
Contact IR
FAQs
Email Alerts
Normal
Press release year list
2021
2020
2019
2018
2017
2016
2015
2014
10/01/2014
AuraSense Therapeutics Expands Leadership Team
Download
PDF format download (opens in new window)
07/23/2014
AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer
Download
PDF format download (opens in new window)
06/17/2014
AuraSense Therapeutics Completes $13.6 Million Series C Equity Investment
Download
PDF format download (opens in new window)